Market Closed -
Australian S.E.
02:10:38 2024-07-04 am EDT
|
5-day change
|
1st Jan Change
|
0.02
AUD
|
0.00%
|
|
0.00%
|
-44.44%
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
17.29
|
19.39
|
32.88
|
497.9
|
129.2
|
82
|
Enterprise Value (EV)
1 |
13.96
|
15.11
|
29.8
|
477.8
|
120.1
|
80.58
|
P/E ratio
|
-4.74
x
|
-4.64
x
|
-9.8
x
|
-74
x
|
-12
x
|
-6.33
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
17.6
x
|
70.2
x
|
26
x
|
217
x
|
170
x
|
224
x
|
EV / Revenue
|
14.2
x
|
54.7
x
|
23.5
x
|
208
x
|
158
x
|
220
x
|
EV / EBITDA
|
-5.53
x
|
-4.84
x
|
-10.1
x
|
-79.5
x
|
-11.6
x
|
-8.39
x
|
EV / FCF
|
3.33
x
|
-12.5
x
|
-19.9
x
|
-186
x
|
-15.4
x
|
-15.8
x
|
FCF Yield
|
30%
|
-7.98%
|
-5.03%
|
-0.54%
|
-6.48%
|
-6.33%
|
Price to Book
|
4.32
x
|
4.58
x
|
10.4
x
|
23.6
x
|
10.5
x
|
34.5
x
|
Nbr of stocks (in thousands)
|
1,152,757
|
1,491,708
|
1,644,091
|
1,952,680
|
1,987,875
|
2,049,939
|
Reference price
2 |
0.0150
|
0.0130
|
0.0200
|
0.2550
|
0.0650
|
0.0400
|
Announcement Date
|
9/28/18
|
8/27/19
|
8/28/20
|
8/31/21
|
8/23/22
|
8/29/23
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
0.9813
|
0.2763
|
1.266
|
2.299
|
0.7609
|
0.3657
|
EBITDA
1 |
-2.525
|
-3.121
|
-2.947
|
-6.013
|
-10.38
|
-9.602
|
EBIT
1 |
-2.838
|
-3.308
|
-3.133
|
-6.221
|
-10.72
|
-10.13
|
Operating Margin
|
-289.2%
|
-1,197.33%
|
-247.46%
|
-270.54%
|
-1,408.85%
|
-2,770.99%
|
Earnings before Tax (EBT)
1 |
-3.385
|
-3.297
|
-3.127
|
-6.216
|
-10.72
|
-12.65
|
Net income
1 |
-3.636
|
-3.297
|
-3.127
|
-6.216
|
-10.72
|
-12.65
|
Net margin
|
-370.48%
|
-1,193.15%
|
-246.97%
|
-270.33%
|
-1,408.48%
|
-3,460.06%
|
EPS
2 |
-0.003162
|
-0.002800
|
-0.002040
|
-0.003447
|
-0.005422
|
-0.006317
|
Free Cash Flow
1 |
4.192
|
-1.207
|
-1.499
|
-2.566
|
-7.785
|
-5.098
|
FCF margin
|
427.19%
|
-436.68%
|
-118.42%
|
-111.58%
|
-1,023.18%
|
-1,393.96%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
9/28/18
|
8/27/19
|
8/28/20
|
8/31/21
|
8/23/22
|
8/29/23
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
3.33
|
4.28
|
3.08
|
20.1
|
9.07
|
1.41
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
4.19
|
-1.21
|
-1.5
|
-2.57
|
-7.79
|
-5.1
|
ROE (net income / shareholders' equity)
|
-61%
|
-80%
|
-84%
|
-51.1%
|
-64%
|
-172%
|
ROA (Net income/ Total Assets)
|
-7.05%
|
-44.8%
|
-45.1%
|
-28.2%
|
-34.4%
|
-61.4%
|
Assets
1 |
51.53
|
7.365
|
6.928
|
22.05
|
31.14
|
20.6
|
Book Value Per Share
2 |
0
|
0
|
0
|
0.0100
|
0.0100
|
0
|
Cash Flow per Share
2 |
0
|
0
|
0
|
0.0100
|
0.0100
|
0
|
Capex
1 |
0.22
|
0.08
|
0.27
|
0.21
|
3.12
|
0.69
|
Capex / Sales
|
22.31%
|
28.31%
|
21.36%
|
9.27%
|
409.79%
|
188.89%
|
Announcement Date
|
9/28/18
|
8/27/19
|
8/28/20
|
8/31/21
|
8/23/22
|
8/29/23
|
|
1st Jan change
|
Capi.
|
---|
| -44.44% | 33.15M | | +16.59% | 44.44B | | +41.02% | 39.84B | | -10.62% | 37.68B | | +29.92% | 31.46B | | -9.23% | 27.02B | | +12.34% | 26.29B | | +41.53% | 13.8B | | +31.49% | 12.46B | | -7.40% | 11.26B |
Other Biotechnology & Medical Research
|